480
Participants
Start Date
May 17, 2010
Primary Completion Date
October 11, 2011
Study Completion Date
October 11, 2011
GSK2202083A vaccine
3 doses given at 2, 4 and 12 months of age
Prevenar 13®
3 co-administered doses
Infanrix hexa™
3 doses given at 2, 4 and 12 months of age
Menjugate®
3 co-administered doses
Rotarix™
Oral, two doses
GSK Investigational Site, Aix-en-Provence
GSK Investigational Site, Porta Westfalica
GSK Investigational Site, Löhne
GSK Investigational Site, Detmold
GSK Investigational Site, Floirac
GSK Investigational Site, Eschwege
GSK Investigational Site, Wolfenbüttel
GSK Investigational Site, Dax
GSK Investigational Site, Heiligenhaus
GSK Investigational Site, Solingen
GSK Investigational Site, Kleve-Materborn
GSK Investigational Site, Willich
GSK Investigational Site, Trélazé
GSK Investigational Site, Essey-lès-Nancy
GSK Investigational Site, Trier
GSK Investigational Site, Mainz
GSK Investigational Site, Frankenthal
GSK Investigational Site, Lingolsheim
GSK Investigational Site, Worms
GSK Investigational Site, Stuttgart
GSK Investigational Site, Schwäbisch Hall
GSK Investigational Site, Le Havre
GSK Investigational Site, Kehl
GSK Investigational Site, Tuttlingen
GSK Investigational Site, Munich
GSK Investigational Site, Draguignan
GSK Investigational Site, Berchtesgaden
GSK Investigational Site, Nördlingen
GSK Investigational Site, Bad Saulgau
GSK Investigational Site, Bindlach
GSK Investigational Site, Vancouver
GSK Investigational Site, Winnipeg
GSK Investigational Site, Hamilton
GSK Investigational Site, Nice
Lead Sponsor
GlaxoSmithKline
INDUSTRY